Market Cap 13.01B
Revenue (ttm) 705.14M
Net Income (ttm) -453.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -64.37%
Debt to Equity Ratio 0.00
Volume 480,200
Avg Vol 2,485,534
Day's Range N/A - N/A
Shares Out 161.97M
Stochastic %K 73%
Beta 0.30
Analysts Strong Sell
Price Target $88.95

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 931 9200
Address:
2855 Gazelle Court, Carlsbad, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 6:23 PM
$IONS RSI: 46.05, MACD: 1.1417 Vol: 1.67, MA20: 80.39, MA50: 76.15 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 3:18 PM
Biotech boom in 2025: Can $IONS, $GPCR, $MNPR, and $KOD keep the momentum? IONS soared 120.5% with strong pipeline progress and favorable regulatory developments. GPCR up 127.2% on promising obesity drug data. MNPR skyrocketed 185.9% fueled by positive investor expectations regarding its lead candidate. KOD surged 181.1% on solid late-stage pipeline potential. See the full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-body-25804&ADID=SYND_STOCKTWITS_TWEET_2_2807434_BODY_25804
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 2:18 PM
These biotech names more than doubled in 2025 — momentum or mania? $IONS, $GPCR, $MNPR, and $KOD all surged over 100% in 2025, fueled by policy clarity, a revival in M&A activity, and key clinical wins pushing biotech momentum into 2026. Which of these winners still has room to run — and which could fade? Full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-teaser-25785&ADID=SYND_STOCKTWITS_TWEET_2_2807434_TEASER_25785
0 · Reply
moshepe
moshepe Dec. 22 at 7:27 AM
ARK ETF changes: 📉 $IONS decrease hold by 👇-1.15%👇 📉 $IBTA decrease hold by 👇-69.99%👇
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:19 PM
$IONS: Actionable Trade Alert Market Context: The stock is currently trading at $77.63, with a Relative Strength Index (RSI) of 23.46, indicating it is oversold. This suggests a potential reversal or bounce back in price. The 30-day moving average (MA30) is at $77.13, and the 50-day moving average (MA50) is at $75.14, indicating a bullish trend may form if the price breaks above these levels. Directional Bias: Given the low RSI and proximity to MA30, we anticipate a bullish reversal. The 60-day high of $83.61 provides a clear upside target, while the 60-day low of $62.19 indicates strong support. Trade Plan: - Suggested Entry: $78.00 - Stop Loss: $75.00 (3.9% risk) - Take Profit Targets: 1. $81.00 (3.9% gain) 2. $84.00 (7.7% gain) 3. $91.00 (17% gain) This setup offers a favorable risk-reward ratio with a potential ROI exceeding 17% on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
StockAnalyst_SA
StockAnalyst_SA Dec. 17 at 9:46 PM
12/17 Notable Flow $CRWV 100 C 03/20/2026 $23.4M 4.04avg 55% OTM $ETHA 16 P 02/20/2026 $781K .62avg 25% OTM $IBIT 49 C 01/16/2026 $2.9M 2.72avg $IONS 75 P 01/16/2026 $1.1M 3.45avg (Above the Ask) $QQQ 605 C 01/02/2026 $3.2M 8.26avg (Buzzer Beater)
0 · Reply
Quantumup
Quantumup Dec. 17 at 4:46 PM
Piper Sandler Named $ARWR a 2026 Top Pick/⬆️PT to $100/reit'd @ OW $IONS $WVE $RHHBY REGN $TEVA Piper Sandler said in its note to investors: Naming ARWR a Top Pick for 2026 for Redemplo Launch and SHTG Data Arrowhead has launched Redemplo in Familial Chylomicronemia Syndrome. We forecast U.S. FCS sales of at least $625,000 in 4Q:25 and $12.3 million in 2026, which could prove conservative based on Redemplo's superior potency, less frequent quarterly dosing and lower annual price of $60,000 vs. IONIS' (IONS, Bratzel) Tryngolza. We are confident Arrowhead will report positive Phase III Redemplo data in SHTG in 3Q:26 with potential blockbuster label expansion in 2027. Arrowhead expects to report initial ARO-INHBE data in January, ARO-ALK7 and ARO-DIMER-PA in mid'26 and potentially ARO-MAPT data in 2026. Arrowhead holds pro forma cash of ~$1.18 billion to fund operations into 2028. We reiterate our Overweight rating and are increasing our target to $100 from $70 by adding pipeline value.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 3:07 PM
RBC Capital has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Outperform with a price target of 95.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Dec. 17 at 3:05 PM
$IONS RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $95
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:05 AM
$IONS: The last close at $78.37 indicates a stable position within the recent trading range. The RSI at 49.37 suggests that the stock is neither overbought nor oversold, indicating potential for upward movement. The MA30 at $76.86 and MA50 at $74.81 support a bullish bias, as the price is above these moving averages, signaling strength. Market context shows a 60D high of $83.61, which presents a potential resistance level. Given the ATR of 2.2, we can expect reasonable volatility. Actionable Trade Plan: - Suggested Entry: $78.50 - Stop Loss: $75.00 (3.2% risk) - Take Profit Targets: 1. $81.00 (3.2% gain) 2. $83.00 (5.7% gain) 3. $91.50 (16.8% gain) This plan offers a solid risk-reward ratio with the potential for over 17% ROI on the third target. Monitor price action closely for adjustments. https://privateprofiteers.com
0 · Reply
Latest News on IONS
Biogen Completes Acquisition of Alcyone Therapeutics

Nov 14, 2025, 4:05 PM EST - 5 weeks ago

Biogen Completes Acquisition of Alcyone Therapeutics

BIIB


Ionis to present at upcoming investor conferences

Nov 12, 2025, 4:00 PM EST - 6 weeks ago

Ionis to present at upcoming investor conferences


Ionis to hold third quarter 2025 financial results webcast

Oct 16, 2025, 7:05 AM EDT - 2 months ago

Ionis to hold third quarter 2025 financial results webcast


Ionis' brain disorder drug shows promise in clinical trial

Sep 22, 2025, 7:10 AM EDT - 3 months ago

Ionis' brain disorder drug shows promise in clinical trial


Ionis to host investors and analysts for Innovation Day 2025

Sep 8, 2025, 4:00 PM EDT - 3 months ago

Ionis to host investors and analysts for Innovation Day 2025


Is The 35% Rally In IONS Stock Just The Beginning?

Sep 3, 2025, 10:41 AM EDT - 4 months ago

Is The 35% Rally In IONS Stock Just The Beginning?


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 4 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN MRNA RGEN


US FDA approves Ionis' drug for rare genetic disorder

Aug 21, 2025, 11:58 AM EDT - 4 months ago

US FDA approves Ionis' drug for rare genetic disorder


OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 24 at 6:23 PM
$IONS RSI: 46.05, MACD: 1.1417 Vol: 1.67, MA20: 80.39, MA50: 76.15 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 3:18 PM
Biotech boom in 2025: Can $IONS, $GPCR, $MNPR, and $KOD keep the momentum? IONS soared 120.5% with strong pipeline progress and favorable regulatory developments. GPCR up 127.2% on promising obesity drug data. MNPR skyrocketed 185.9% fueled by positive investor expectations regarding its lead candidate. KOD surged 181.1% on solid late-stage pipeline potential. See the full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-body-25804&ADID=SYND_STOCKTWITS_TWEET_2_2807434_BODY_25804
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 2:18 PM
These biotech names more than doubled in 2025 — momentum or mania? $IONS, $GPCR, $MNPR, and $KOD all surged over 100% in 2025, fueled by policy clarity, a revival in M&A activity, and key clinical wins pushing biotech momentum into 2026. Which of these winners still has room to run — and which could fade? Full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-teaser-25785&ADID=SYND_STOCKTWITS_TWEET_2_2807434_TEASER_25785
0 · Reply
moshepe
moshepe Dec. 22 at 7:27 AM
ARK ETF changes: 📉 $IONS decrease hold by 👇-1.15%👇 📉 $IBTA decrease hold by 👇-69.99%👇
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:19 PM
$IONS: Actionable Trade Alert Market Context: The stock is currently trading at $77.63, with a Relative Strength Index (RSI) of 23.46, indicating it is oversold. This suggests a potential reversal or bounce back in price. The 30-day moving average (MA30) is at $77.13, and the 50-day moving average (MA50) is at $75.14, indicating a bullish trend may form if the price breaks above these levels. Directional Bias: Given the low RSI and proximity to MA30, we anticipate a bullish reversal. The 60-day high of $83.61 provides a clear upside target, while the 60-day low of $62.19 indicates strong support. Trade Plan: - Suggested Entry: $78.00 - Stop Loss: $75.00 (3.9% risk) - Take Profit Targets: 1. $81.00 (3.9% gain) 2. $84.00 (7.7% gain) 3. $91.00 (17% gain) This setup offers a favorable risk-reward ratio with a potential ROI exceeding 17% on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
StockAnalyst_SA
StockAnalyst_SA Dec. 17 at 9:46 PM
12/17 Notable Flow $CRWV 100 C 03/20/2026 $23.4M 4.04avg 55% OTM $ETHA 16 P 02/20/2026 $781K .62avg 25% OTM $IBIT 49 C 01/16/2026 $2.9M 2.72avg $IONS 75 P 01/16/2026 $1.1M 3.45avg (Above the Ask) $QQQ 605 C 01/02/2026 $3.2M 8.26avg (Buzzer Beater)
0 · Reply
Quantumup
Quantumup Dec. 17 at 4:46 PM
Piper Sandler Named $ARWR a 2026 Top Pick/⬆️PT to $100/reit'd @ OW $IONS $WVE $RHHBY REGN $TEVA Piper Sandler said in its note to investors: Naming ARWR a Top Pick for 2026 for Redemplo Launch and SHTG Data Arrowhead has launched Redemplo in Familial Chylomicronemia Syndrome. We forecast U.S. FCS sales of at least $625,000 in 4Q:25 and $12.3 million in 2026, which could prove conservative based on Redemplo's superior potency, less frequent quarterly dosing and lower annual price of $60,000 vs. IONIS' (IONS, Bratzel) Tryngolza. We are confident Arrowhead will report positive Phase III Redemplo data in SHTG in 3Q:26 with potential blockbuster label expansion in 2027. Arrowhead expects to report initial ARO-INHBE data in January, ARO-ALK7 and ARO-DIMER-PA in mid'26 and potentially ARO-MAPT data in 2026. Arrowhead holds pro forma cash of ~$1.18 billion to fund operations into 2028. We reiterate our Overweight rating and are increasing our target to $100 from $70 by adding pipeline value.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 3:07 PM
RBC Capital has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Outperform with a price target of 95.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Dec. 17 at 3:05 PM
$IONS RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $95
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:05 AM
$IONS: The last close at $78.37 indicates a stable position within the recent trading range. The RSI at 49.37 suggests that the stock is neither overbought nor oversold, indicating potential for upward movement. The MA30 at $76.86 and MA50 at $74.81 support a bullish bias, as the price is above these moving averages, signaling strength. Market context shows a 60D high of $83.61, which presents a potential resistance level. Given the ATR of 2.2, we can expect reasonable volatility. Actionable Trade Plan: - Suggested Entry: $78.50 - Stop Loss: $75.00 (3.2% risk) - Take Profit Targets: 1. $81.00 (3.2% gain) 2. $83.00 (5.7% gain) 3. $91.50 (16.8% gain) This plan offers a solid risk-reward ratio with the potential for over 17% ROI on the third target. Monitor price action closely for adjustments. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 8:45 PM
Leerink Partners updates rating for Ionis Pharmaceuticals ( $IONS ) to Outperform, target set at 85 → 100.
0 · Reply
nocats
nocats Dec. 15 at 5:44 PM
$IONS Maybe just fake news, but something to consider.https://www.infowars.com/posts/fda-may-slap-covid-vaccines-with-black-box-warning
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:39 AM
$IONS: Current market context shows a strong upward trend, with the last close at $80.82 and an RSI of 66.9 indicating bullish momentum but nearing overbought territory. The price is above both the 30-day MA (76.75) and the 50-day MA (74.64), confirming a strong bullish bias. The stock is currently trading close to its 60-day high of $83.61, suggesting potential resistance at that level. Actionable Trade Alert: - Suggested Entry: $81.00 - Stop Loss: $78.00 (3.5% below entry) - Take Profit Targets: - Target 1: $83.00 (2.5% gain) - Target 2: $85.00 (4.9% gain) - Target 3: $95.00 (17.3% gain) With a potential ROI of over 17% on Target 3, this trade plan capitalizes on the bullish trend while managing risk effectively. Monitor the price action closely around the 60-day high for confirmation. https://privateprofiteers.com
0 · Reply
NJgolfer
NJgolfer Dec. 13 at 10:12 PM
$IONS looking into 2026, likely above $100 as long as mkt doesn't melt down. Have to be patient as this is really extended from key support and MAs
0 · Reply
Doozio
Doozio Dec. 13 at 3:15 PM
$IONS base out from here a bit and the huckleberries will be below da YUGE $$$$. All yo needed was ⏰ for 🐒🍌🧠⏰♾️
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:32 PM
$IONS: The last close at $79.73 indicates a strong bullish momentum, but the RSI at 70.83 suggests it is nearing overbought territory. The proximity to the 60D high of $83.61 indicates potential resistance ahead. However, the moving averages (MA30 at $76.55 and MA50 at $74.41) support a bullish trend, with the price above these averages. Action Plan: - Entry: Consider entering at $79.50 to capture potential upward movement. - Stop Loss: Set at $77.00 to limit downside risk. - Take Profit Targets: - TP1: $82.00 (approximately 3.2% gain) - TP2: $85.00 (approximately 6.8% gain) - TP3: $93.50 (approximately 17.3% gain) The targets are set based on resistance levels and potential price action. Maintain a close watch on RSI for signs of reversal. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Dec. 11 at 12:47 PM
RBC Capital⬆️ $ARWR's PT to $80 from $52 and reiterated at an Outperform rating. $IONS $WVE Here's what RBC Capital said in its note: https://x.com/Quantumup1/status/1999097852421669299?s=20
2 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:36 AM
$IONS: Actionable Trade Alert Market Context: The stock closed at $78.86, showing strength as it approaches the 60D high of $83.61. The RSI at 63.69 indicates bullish momentum, but caution is warranted as it approaches overbought territory. Directional Bias: The price is above the 30-day MA of $76.12 and the 50-day MA of $73.86, indicating a strong upward trend. The proximity to the 60D high suggests potential resistance, but the overall trend remains positive. Trade Plan: - Suggested Entry: $79.50 (breakout above recent resistance) - Stop Loss: $76.00 (below the 30-day MA) - Take Profit Targets: 1. $82.00 (10% ROI) 2. $85.00 (15% ROI) 3. $92.00 (17% ROI) This plan allows for a strategic entry with defined risk and multiple profit-taking opportunities. Ensure to monitor market conditions closely. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 5:59 PM
B of A Securities updates rating for Ionis Pharmaceuticals ( $IONS ) to Buy, target set at 86 → 97.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:24 PM
$IONS: The stock closed at $81.99, with a high RSI of 79.8 indicating overbought conditions, which suggests a potential pullback. However, the stock is above its 30-day MA of $75.94 and 50-day MA of $73.58, indicating a bullish trend in the short term. The recent 60-day high of $83.61 presents a resistance level, while the low of $60.41 provides a solid support base. Action Plan: - Suggested Entry: $81.99 - Stop Loss: $79.56 (below ATR, 1.5x ATR) - Take Profit Targets: 1. $83.00 (2.5% gain) 2. $84.50 (3.5% gain) 3. $96.00 (17.1% gain) The directional bias leans bullish due to the strong short-term moving averages, but caution is warranted given the high RSI. Monitor for any signs of reversal near resistance levels. https://privateprofiteers.com
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 8 at 1:54 PM
Our earlier post compared $NBIX Crenessity product revenue post FDA approval/launch to peers acquired in that $10B range like Verona & Immunogen suggesting, but not confirming, NBIX's Crenessity might be worthj a similar number in a M&A exit. Here we show valuation & revenue projection data for the 10 commercial-stage non-oncology focused peers with market caps ranging from $6 to $15B. NBIX's Ingrezza is a powerhouse by itself on track to doing $2.5B in FY25. This is not investment advice but we really like NBIX. $RYTM has a great drug with multiple catalysts nearing including a PDUFA & a P3 read. Still RYTM trades at a very high multiple of analyst revenue estimates compared to these peers. $CORT Relacorilant has an upcoming PDUFA in Cushing's followed by ovarian cancer. We considered CORT non-oncology but that will change if approved. $BMRN is a great company but to us appears a textbook example of the risks of staying independent. BMRN is down ~50% from Xmas 2015. $IONS was the same ?
2 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:24 AM
$IONS: Current market context shows a strong bullish sentiment with the last close at $81.81 and an RSI of 83.95, indicating overbought conditions. The price is above the 30-day MA of $75.23 and the 50-day MA of $72.85, reinforcing a bullish directional bias. The recent high of $83.61 suggests resistance, while the low of $60.41 provides a solid support level. Actionable Trade Alert: - Suggested Entry: $81.81 - Stop Loss: $79.00 (approx. 3.4% risk) - Take Profit Targets: 1. $84.50 (approx. 3.1% gain) 2. $87.00 (approx. 6.9% gain) 3. $95.00 (approx. 16.1% gain) With a potential ROI of over 17% on the third target, this trade plan aligns with current momentum. Monitor RSI for signs of reversal as the trade progresses. https://privateprofiteers.com
0 · Reply